A recent study reveals that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional diet and exercise programs.
Published data in a major medical journal points out that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.
"People using such medications need to be informed of the risk of rapid weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight within about a year and a half.
Analyzing Approaches
The research, which examined dozens of trials involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone generally see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors believe the mode of action of the injections accounts for the amplified weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, given the significant potential of relapse, the therapy should be considered ongoing.
This perspective is reinforced by drug manufacturers, who note that the findings "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
User Testimonies
People who have discontinued the medication report a intense resurgence of cravings.
"I experienced a switch flipping and I was suddenly ravenous," said an individual.
This challenge is worsened if users have not established sustainable dietary or behavioural changes during therapy.
Widespread Use
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, researchers stress that while the jabs are powerful tools for weight loss, they are not a standalone cure and long-term success hinges on ongoing lifestyle changes.
